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ABSTRACT
A MATHEMATICAL MODEL OF ACUTE RESPONSE OF
PARATHYROID HORMONE TO CHANGES IN PLASMA
IONIZED CALCIUM IN NORMAL HUMANS
MAY 2008
RAJIV P. SHRESTHA
B.E., INSTITUTE OF ENGINEERING, PULCHOWK CAMPUS, KATHMANDU,
NEPAL
M.S.M.E., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yossi Chait and Professor Christopher V. Hollot
A complex bio-mechanism, referred to as calcium homeostasis, regulates plasma ionized
calcium (Ca++) concentration in the human body to within a narrow physiologic range which
is crucial for maintaining normal physiology and metabolism. Various metabolic disorders
and pathologic conditions originate from acute and/or chronic disturbances/disorders in
calcium homeostatic system. This system relies on numerous sub-systems which operate in
different time-scales ranging from minutes to weeks. In this thesis we focus on a particular
sub-system that operates on the time-scale of minutes; the dynamics involves the response
of the parathyroid glands to acute changes in plasma Ca++ concentration. We develop a
two-pool, linear time-varying model describing the dynamics of the sub-system. We show
that this model can predict dynamics observed in clinical tests of induced hypo- and hyper-
vi
calcemia in normal humans. In addition, we develop a new protocol for the construction of
a Ca-PTH reverse sigmoid curve based on the mathematical model. This protocol removes
deficiencies in current protocols in that the resulting curve is invariant with respect to the
subject’s axis dynamics and calcium clamp test dynamics.
vii
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CHAPTER 1
INTRODUCTION
Calcium homeostasis refers to a complex bio-mechanism that regulates plasma ionized
calcium (Ca++) concentration in the human body to within a narrow physiologic range which
is crucial for maintaining normal physiology and metabolism. Plasma Ca++ plays a vital
role in normal functioning of muscles, nerves, platelets, neutrophils, and coagulation factors,
cell growth, cell division, secretion of hormones and other regulators [1], and mineralization
of bones [2]. This complex bio-system comprises numerous sub-systems interconnected via
positive and negative feedback pathways.
Various metabolic disorders and pathologic conditions originate from acute and/or chronic
disturbances/disorders in the calcium homeostasis. They can be caused by any one or a com-
bination of the following factors: a) changes in plasma Ca++ levels and/or vitamin D levels
by a physiologically significant amount, b) impaired synthesis and/or secretion of parathy-
roid hormone (PTH), and c) pathological conditions of parathyroid glands and kidneys.
These disorders may affect normal bone remodeling process causing various metabolic bone
diseases, such as osteoporosis, a major public health concern in the United States [3, 4], be-
sides causing many other abnormalities and disease conditions (eg., primary and secondary
hyperparathyroidism).
The present understanding of calcium homeostasis and its disorders is based on the tra-
ditional approach of biological and medical science which involves discovering various signal-
ing pathways, identifying critical bio-markers, and employing statistical analysis. However,
calcium homeostasis is a sophisticated bio-system where numerous sub-systems interact at
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different time-scales. A perturbation in one sub-system has corresponding effects in the in-
terconnected sub-systems and these in turn have effects on the other sub-systems. These
cascade-effects propagate in positive and negative feedback pathways in multiple directions.
It becomes impractical, if not impossible, to keep track of all of these interactions in order
to derive an understanding of the bio-system as a whole using the traditional approach.
Systems biology, an emerging science, relies on the integration of mathematical models for
individual sub-systems into a single model, enabling us to study the effects of disturbances
in the various inputs, pools and processes of the overall bio-system [5, 6].
We took the systems biology approach in our overall calcium homeostasis modeling ef-
forts. We first developed a qualitative model of the overall bio-system. Based on this qual-
itative model, substantial progress was made towards the development of a mathematical
model (not presented in this thesis). However, during this process we realized that existing
models for a very important aspect of calcium homeostasis, the acute dynamical interaction
between plasma Ca++ and PTH (called the Ca-PTH axis for ease of notation) appeared
deficient. To address this issue we decided to focus our research goal only on this axis of the
bio-system.
The thesis is organized as follows. In Chapter 2, we present a detailed qualitative model
of overall calcium homeostasis in a normal human, and explain why the Ca-PTH axis can
be isolated from the overall bio-system. In Chapter 3, we develop a mathematical model
of the acute Ca-PTH axis dynamics. In Chapter 4, we address the inconsistency in current
procedures for deriving the calcium-PTH reverse sigmoid curve. This curve could potentially
be used as an important bio-marker of diseases disrupting calcium homeostasis and to assess
the effectiveness of treatment protocols, based on the mathematical model developed. The
conclusions are given in Chapter 5.
The specific contributions of this thesis work are:
2
1. A new mathematical model describing the response of plasma PTH to acute changes
in plasma Ca++ concentration in normal humans has been developed. This model can
successfully predict dynamics observed in clinical tests of induced hypo- and hyper-
calcemic clamp tests.
2. A new method of generating Ca-PTH reverse sigmoid curve has been formulated. The
resulting curve properties are independent of the manner by which the induced calcemic
clamp test is conducted.
3
CHAPTER 2
QUALITATIVE MODEL OF CALCIUM HOMEOSTASIS
A detailed qualitative model describing the interactions between various components
and signalling pathways of calcium homeostasis is presented in this chapter. We begin by
describing the major pools and fluxes of calcium next.
2.1 Major pools and fluxes
The intestine, bone, kidney, and plasma are the four major pools of Ca++ in the human
body. There is about 1-2 kg of calcium in a healthy adult, most of which (99%) is in the
form of hydroxypatite crystals in teeth and bones [7]. Of the remaining, 50% constitutes the
ionized or ‘free’ calcium in plasma, 40% is bound reversibly to proteins, and 10% is complexed
with citrate and phosphate [1]. The average total plasma calcium concentration in the human
body is 2.1-2.6 mmol/L [8]. At normal physiological state, about 1.1-1.3 mmol/L is ionized
calcium, 0.9-1.1 mmol/L is protein-bound calcium, 0.18 mmol/L is complexed calcium and
180 nmol/L is intracellular free calcium [8]. The ionized form of calcium, which is just 0.5%
of the total body calcium, is metabolically active [1] and tightly regulated by the homeostatic
system. The condition when Ca++ level falls below the normal range is called hypocalcemia
and the condition when it climbs above the normal range is called hypercalcemia.
An overall daily Ca++ balance in the plasma of a healthy adult is maintained by fluxes
of calcium between the plasma and the intestine, bone and kidney as shown in Figure 2.1.
Intestine receives calcium from the external environment through diet. A normal daily
diet contains about 1,000 mg of calcium. During the process of digestion only about 300
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Figure 2.1. Daily calcium balance in a normal adult. The arrows show the direction of
flux. Numerical values from [9].
mg are absorbed from the intestine into the plasma and roughly 125 mg are effluxed back
into the intestine, which is cleared out through fecal excretion along with the unabsorbed
fraction. Hence, the net dietary uptake of calcium into the plasma pool is 175 mg. There
is an exchange of 500 mg of calcium to and from the bone with the plasma but the net
exchange is zero assuming that in the time-scales of minutes to hours there is no change in
bone mass. On a daily basis, 10,000 mg of calcium are ultra-filtered out of the plasma into
nephrons in the kidney, where about 9,825 mg of calcium are reabsorbed. The net removal
of calcium via the kidney is 175 mg per day, which is excreted in urine. Thus, the additional
dietary calcium that enters into the circulation is excreted out and a normal plasma calcium
concentration is maintained.
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The flux exchange described above is actively regulated by two chief hormones: the
metabolically active form of vitamin D and PTH. The metabolism and regulation of vitamin
D and PTH are presented in the next sections, respectively.
2.2 Vitamin D metabolism and regulation
The general steps in the metabolism of vitamin D are shown in Figure 2.2 (the presen-
tation here follows the detailed exposition in [10]). There are two sources of vitamin D in
the human body: daily diet and skin. Daily diet provides vitamin D2 (ergocalciferol) and
7-dehydro
cholesterol
25 Dihydroxy
Vitamin D3
25 Dihydroxy
Vitamin D2
1, 25 Dihydroxy
Vitamin D2
Vitamin D3
Conversion
Conversion
1, 25 Dihydroxy
Vitamin D3Conversion
Conversion
Vitamin D3
Vitamin D2
Conversion
Liver Kidney
uv-Light
Skin
F
ro
m
 D
ie
t
Storage in Adipose 
Tissues
Plasma Pool of 25 D Plasma Pool of 1, 25 D
Figure 2.2. The general steps in vitamin D metabolism. Dotted arrows mean conversion
and solid arrows mean transportation.
vitamin D3 (cholecalciferol), whereas in skin, 7-dehydrocholesterol is converted into vitamin
D3 by exposure to uv-light. The biological actions of both forms of vitamin D is consid-
ered to be the same, hence, the term vitamin D is used to denote both forms in this work.
Vitamin D does not circulate for long in the blood stream. It is immediately taken up by
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adipose tissue for storage or by liver for 25-hydroxylation to form 25 hydroxy vitamin D1. 1,α
hydroxylation of 25D occurs in the kidney to form the metabolically active 1,25 dihydroxy
vitamin D2. In humans, tissue storage of vitamin D can last for months or even years. 25D
is the major circulating form of vitamin D.
In a normal individual, there is an ample supply of Vitamin D to plasma directly from
diet, skin, and storage in the adipose. The conversion of vitamin D to 25D in the liver is
only loosely regulated [10]. However, the conversion of 25D to 1,25D in the kidney is tightly
regulated by renal α hydroxylase enzyme and it has been established that the kidney is the
major source of the circulating pool of 1,25D [10]. For our modeling purpose, the different
steps in the vitamin D metabolism process have been lumped into a high-level schematic
diagram as shown in Figure 2.3. Next, we present the bio-synthesis and secretion of PTH
and their regulations.
Conversion
Plasma
(DP)
Plasma
(25DP)
Plasma
(1,25DP)
Conversion
Liver Kidney
Kidney
(?K)
Figure 2.3. A high-level schematic diagram of the major steps in the metabolism of vitamin
D and its regulation. The darkened solid arrow indicates stimulation.
2.3 PTH bio-synthesis and secretion and their regulation
There are four parathyroid glands, each weighing 40 mg on average, located adjacent
to the thyroid gland in the neck [8] as shown in Figure 2.4(a). The chief cells, shown in
1We use 25D to denote 25 hydroxy vitamin D.
2We use 1,25D to denote 1,25 dihydroxy vitamin D.
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Figure 2.4(b), are the predominant cells in the parathyroid glands [11]. PTH is synthesized
Parathyroid Glands. Reproduced from: Atla
Larynx
Thyroid
Parathyroid
Glands
Trachea
(a) Anatomy of the parathyroid glands. Reproduced
from [12].
Chief Cell
(b) Histology of the parathyroid gland.
Stain: Hematoxylin-eosin.550x. Repro-
duced from [13].
Figure 2.4. Anatomy and histology of parathyroid glands.
and stored in the cytoplasmic vesicles of the chief cells. Normally, only about 20% of the
cell population is actively secreting PTH [11]. Next, a simple understanding of these steps
involved is presented based on [14, 15]. Figure 2.5 summarizes the steps.
The first step in the biosynthesis of PTH is the transcription process in which genetic
information is transferred from the DNA (Deoxyribonucleic acid) to a pre-mRNA (pre-
messenger ribonucleic acid) in the nucleus of the parathyroid cell. The post-transcriptional
process follows. The pre-mRNAmatures into an mRNA that is transported to the cytoplasm,
the process being called transportation. The next step is the translation where the genetic
information in the mRNA is translated into a specific polypeptide, a larger precursor of
PTH, called pre-proPTH containing 115 amino acids. This process occurs in the endoplasmic
reticulum-bound polyribosomes. The pre-proPTH is then cleaved in the rough endoplasmic
reticulum to produce a 90 amino acid intermediate precursor of PTH called proPTH. This
8
Transportation
Cytoplasm
Nucleus
Exocytosis
Parathyroid Chief Cell
Translation
1st Cleavage2nd Cleavage
Pre-mRNA mRNA
Plasma
(PTHP)
ProPTH PreProPTH
DNA
mRNA
Legend
Pool
Flux
Conversion
Stimulation
Inhibition
Decayø
Post-Transcription
Transcription
PTHC
ø
Calcium Sensing Receptor
VDR
Figure 2.5. A schematic diagram describing various steps involved in PTH bio-synthesis
inside a parathyroid chief cell. PTH thus synthesized is stored in vesicles inside the cells.
PTH is secreted from the cells by exocytosis process.
process is called first cleavage. The second cleavage occurs in the golgi complex in the
cytoplasm to finally produce the PTH which accumulates in the vesicles. In response to
secretory stimulus caused by decrease in plasma Ca++ concentration to calcium sensing
receptors (CaR) on the cell membrane [16], the membrane of the storage vesicle fuses with
the cell membrane and PTH is released from the cell into circulation. This process is called
exocytosis.
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PTH bio-synthesis is regulated by plasma 1,25D during the transcriptional process [17]
and by Ca++ during post-transcriptional process [18] as depicted in the Figure 2.6. The
1,25D form of vitamin D, with the plasma half-life of 12 to 15 hours [1], regulates the long-
term parathyroid secretion function. It has been termed as a day-to-day regulator of calcium
Transportation
Cytoplasm
Nucleus
Exocytosis
Chief Cell
Translation
ø
ø
ø
øø
1st Cleavage2
nd Cleavage
Pre-mRNA mRNA
[PTH]P
ProPTH PreProPTH
DNA
mRNAø
Legend
Pool
Flux
Conversion
Stimulation
Inhibition
Decayø
[1,25D]P
Post-Transcription
Transcription
VDR
[C
a] P
[PTH]C
ø
Figure 2.6. A schematic diagram showing the regulation of PTH bio-synthesis and secretion
by 1,25D and calcium.
homeostasis [1]. Higher concentrations of 1,25D inhibit the transcription of the PTH gene
[17] through signalling from the nuclear [8] vitamin D receptor (VDR). The effect occurs
within 2 hours [1]. A decrease in PTH mRNA levels to less than 4% of controls was observed
within 48 hours in rats that were injected with amounts of 1,25D which did not increase
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their calcium levels [17]. The time-scale of this regulation of PTH synthesis by 1,25D cannot
be pin-pointed. However, a time-scale of hours to days can be assumed based on [1, 17, 19].
Plasma Ca++ regulates PTH bio-synthesis during the post-transcriptional process. The
regulation occurs by affecting the mRNA stability [18]. An increase in plasma Ca++ concen-
tration decreases the overall PTH bio-synthesis by degrading the mRNA faster. Conversely,
a decrease in plasma Ca++ concentration increases the overall PTH bio-synthesis by increas-
ing the nuclear mRNA half-life. No known major regulatory effects have been observed at
the translational and post-translational levels [14]. The time-scale of this regulation has been
suggested to range from hours to days in [1, 14].
The regulation of exocytosis in response to changes in plasma Ca++ levels occurs strictly
by signaling pathways involving calcium sensing receptors (CaR) located on the cell mem-
brane of the chief cells of the parathyroid glands [16]. An increase in the plasma Ca++
concentration results in a decrease in PTH secretion. Conversely, a decrease in the plasma
Ca++ concentration results in an increase in PTH secretion. The time-scale of the parathy-
roid gland’s response to varying plasma Ca++ concentrations ranges from seconds to minutes
[20, 16]. In our qualitative model of the calcium homeostasis the above described 1,25D and
the plasma Ca++ concentration signaling pathways have been lumped together in terms of an
overall effect on the exocytosis. Next, we put together the descriptions presented in Sections
2.1-2.3 to form a qualitative model of plasma calcium homeostasis.
2.4 Qualitative model of plasma calcium homeostasis
The plasma calcium pool size is maintained by a flux balance with the intestine, bone,
and kidney. The influx of calcium from the intestine consists of both actively- and passively-
regulated channels, whereas the efflux to the intestine is mainly due to passive transportation
(Figure 2.7(a)). The efflux to the kidney involves ultrafiltration, where the filtration occurs
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under high pressure in the glomerular capillaries of the kidney. The influx from the kidney
involves a passive diffusion and an active reabsorption by the nephrons.
A decrease in the plasma Ca++ concentration acutely stimulates (a rise in the plasma
Ca++ concentration inhibits) PTH secretion by exocytosis from the parathyroid cells in a
time-scale of minutes [16]. In the time-scales of hours to days, a decrease in plasma Ca++
concentration increases (a rise in the plasma Ca++ concentration decreases) bio-synthesis
of PTH in the parathyroid cells [14]. PTH in turn stimulates bone calcium resorption and
active renal reabsorption of calcium. PTH also upregulates production of renal α hydroxylase
enzyme in the kidney which upregulates conversion of 25D into 1,25D in the kidney. 1,25D in
turn upregulates active intestinal calcium absorption and active renal calcium reabsorption.
It also downregulates PTH bio-synthesis in the parathyroid cells and production of the
renal α hydroxylase enzyme, resulting in the downregulation of its own production. These
pathways are shown in Figure 2.7(b).
1,25D and PTH play important roles in regulating bone formation and resorption pro-
cesses [8]. This results in the addition or removal of calcium from the plasma pool and the
transportation of it to and from the bone. This process, of course, plays an important role
in plasma calcium homeostasis. In fact, the bone acts as a big reservoir to supply calcium
to the plasma in case of need. Though the exact function of 1,25D and PTH in the bone
remodeling process is not well understood, it has now been generally accepted that 1,25D
upregulates calcium trapping for bone formation [8] and an intermittent rise in PTH helps
in a net positive bone formation [21, 22, 23] resulting in a net flux of calcium from plasma
to bone. A lack of 1,25D and continuous rise in PTH upregulates bone resorption resulting
in a net flux of calcium to the plasma. Phosphate in high concentrations stimulates PTH
secretion and PTH upregulates phosphate clearance through the kidney. The effect of phos-
phate on the parathyroid gland is independent of plasma Ca++ and vitamin D [18]. Thus,
the phosphate pool is not included in the present model.
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Figure 2.7. A qualitative model of plasma calcium homeostasis.
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The response of the parathyroid glands to acute changes in plasma Ca++ concentration
occurs in time-scales of seconds to minutes [16] which involves the exocytosis process. Be-
cause regulation of PTH bio-synthesis by plasma Ca++ and 1,25 D in the chief cells and all
other signaling pathways in the calcium homeostatic system run in the time-scales of hours
to days [18, 17], it is feasible to study the acute response of plasma PTH to changes in
the plasma Ca++ separately from the overall system. We refer to this isolated sub-system
(shown in Figure 2.7(c)) of the overall bio-system as the Ca-PTH axis from here on. Given
that a reasonable amount of information is available about this axis, this thesis focuses on
the development of a mathematical model for this axis, which is presented next in Chapter
3.
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CHAPTER 3
A MATHEMATICAL MODEL OF THE CA-PTH AXIS
In this chapter we develop a model describing the response of PTH to acute changes in
plasma Ca++ concentration (Ca-PTH axis) in humans. To fully appreciate this model, we
first present a literature review of relevant published models.
3.1 Literature review
Our literature survey unraveled numerous models of calcium homeostasis of varying de-
grees of details. The earlier works are theoretical or have utilized data from animals and birds
whereas the recent investigations have utilized data from humans. With the discovery of var-
ious receptors and ligands involved in the signalling pathways within individual sub-systems,
the understanding of the details of calcium homeostasis has progressed substantially. Hence,
most of the recent studies have focussed on modeling particular sub-systems of the calcium
homeostasis, e.g. Ca-PTH axis [19, 20] and bone remodeling process [21, 22, 24].
One of the earliest works relevant to mathematical modeling of calcium homeostasis dates
back to 1963 [25]. A theoretical approach of modeling calcium metabolism was presented. A
central blood calcium pool with a bidirectional calcium flux exchange with both the skeleton
and intestine and a unidirectional flux of calcium to urine were considered. Two schemes
of calcium metabolism were presented. Various options were suggested for the collection of
data required for parametrization of the model. The roles of regulating hormones were not
included in the model.
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Although the role of PTH in the acute regulation of plasma calcium levels was clearly
established as early as 1959 [26] it seems to have been incorporated in a mathematical model
for the first time in 1965 [27]. A model for the regulation of the blood calcium level in rats by
bone metabolism was presented in this paper. It concluded that feedback systems with an
integral control due to parathyroid hormone for a normal rat and a proportional control for
a thyro-parathyroidectomized rat can explain the response of bone metabolism to changes
in blood calcium levels.
Calcium homeostasis based on negative feedback control involving a proportional con-
trol by PTH during hypocalcemia and by calcitonin during hypercalcemia was suggested in
[28]. Linear relationships between PTH secretion and calcium concentration with a negative
slope and between calcitonin secretion and calcium concentration with a positive slope were
assumed. A very simplified model of the Ca-PTH axis in dogs was presented in [29]. Exper-
imental results from normal and thyro-parathyroidectomized dogs were utilized to calculate
model parameters. It was assumed that the action of PTH is limited only to the resorption
of bone and that its effects in the regulation of fluxes to and from the kidney and intestine
are negligible at steady-state.
A theoretical, quasi-linear, lumped-parameter model for calcium homeostasis for mam-
mals based on data from different animals, eg., dogs, rats, rabbits and pigs appears in [30].
PTH and calcitonin were assumed to be the prime hormones. Linear relationships were
assumed between plasma calcium and both plasma calcitonin and plasma PTH. Finally, due
to lack of data to validate the model, it only suggested possible experiments to obtain data
to parameterize the model.
A general mathematical model for calcium homeostasis in birds was presented in [31].
The roles of PTH and 1,25D as regulating hormones for different calcium fluxes between
bone, kidney, intestine, and plasma were taken into consideration. A calcium pool, a PTH
hormone pool, and a 1,25D pool in the plasma, and a 1,25D pool in the intestine were
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considered. A part of the intestinal flux of calcium was assumed to be regulated by 1,25D
and a part of the bone flux of calcium was assumed to be regulated by PTH. The model
also considered the regulation of renal hydroxylase enzyme by PTH, which in turn regulates
the conversion of 25D to 1,25D. An extension to this model was presented in [32] which
included the effects of body growth and energy intake models for chicks. This model utilized
the reverse sigmoidal relationship between PTH secretion and plasma Ca++ concentrations
presented in [33].
The first conclusive study demonstrating the nonlinear nature of the relationship between
PTH secretions and plasma Ca++ level in a bovine, normal human, and pathological human
parathyroid tissue in vitro was presented in [33]. A reverse sigmoidal model bearing four
parameters representing various aspects of the secretion dynamics was presented in the paper.
Further details on this model can be found in Chapter 4.
A proportional-integral feedback control structure was utilized to develop a dynamical
model for calcium homeostasis in healthy dairy cows for longer time-scale of days in [34].
The proportional-integral feedback control was realized by assuming the production of 1,25D
to be proportional to PTH concentration. Nonlinearities were introduced in the form of a
saturation function in the relationships between: 1) PTH and calcium transportation from
the bone to plasma, and 2) plasma Ca++ concentration and calcium transport from the
intestine. These were used to study calcium homeostatic disorder and breakdown in dairy
cows called parturient paresis or milk fever which occasionally affects them after calving. The
results suggested that a reduction in bone remodeling reaction to PTH may cause milk fever.
Moreover, for the breakdown to occur this reduced responsiveness must be accompanied by
reduced gut motility.
A relatively recent attempt to model plasma calcium homeostasis consisting of separate
pools of calcium, phosphate, PTH, calcitriol in plasma, intracellular phosphate, and parathy-
roid gland mass was presented in [35]. The exchangeable pools of calcium and phosphate
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in bone were introduced to model flux exchange between the plasma and bone. Similarly, a
renal 1,α hydroxylase pool, a phosphate pool, and an intestinal calcium pool were utilized to
capture the dynamics involving the kidney and the intestine. Clinical data from a renal fail-
ure case was compared with simulation results with a favorable match. Generally speaking
this model seems to have incorporated all the important aspects and recent understanding
of calcium homeostasis and signalling pathways. However, this model cannot predict the
observed Ca-PTH dynamics for short time-scales of less than 10 minutes. This becomes
evident by comparing simulation results presented in the paper with clinical data for shorter
time-scales presented in [20]. Moreover, the fact that the model uses a single PTH pool
rules out the possibility of achieving dynamics observed in clinical data. A mathematical
proof of the deficiency of the single PTH pool model will be presented in Section 4.4. Short
time-scale dynamics may be important in an overall model of plasma calcium homeostasis,
especially when we incorporate the interaction with bone because the intermittent change
in PTH levels helps in net positive bone formation [21, 22, 23]. A brief review of the two
mathematical models that capture short time-scale Ca-PTH interaction are discussed next.
3.1.1 Ca-PTH axis models
A multi-parameter deconvolution analysis method suggested in [36] was used to study the
tonic and pulsatile nature of PTH secretion in normal humans in [37]. A two-pool, linear,
time-invariant (LTI) model was arbitrarily assumed to represent the Ca-PTH axis. The
model was parameterized using the hypo- and hyper-calcemic clamp test data separately.
The parameterized models were used to estimate the tonic and pulsatile PTH secretion.
For the first time, [19] utilized the biological events in the process of PTH secretion
to derive a two-pool model of Ca-PTH dynamics for short time-scales (in minutes). Two
PTH pools, one in the parathyroid cells and the other in the blood, were considered. An
important simplifying assumption that the change in calcium occurs instantaneously was
18
used to render the model into an LTI system. The presentation in [19] differs from the ones
in [20, 37] in the respect that it utilizes the biological events to explain the origin of the
model. This model, parameterized based on a hypocalcemic clamp test, matched the test
results. Nevertheless, we note that the assumption of an instantaneous change in plasma
calcium levels is not expected to hold in practice. The ability of this model to predict
dynamics of a hypercalcemic clamp test was not explored. Next, we present some clinical
observations on the Ca-PTH axis.
3.2 Clinical observations
A clinical protocol, referred to as an induced calcemic clamp test, is typically employed to
study the status of the Ca-PTH axis. During an induced hypocalcemic clamp test, plasma
Ca++ concentration is decreased by an intravenous infusion of sodium citrate. Similarly,
during an induced hypercalcemic clamp test, plasma Ca++ concentration is increased by an
intravenous infusion of calcium gluconate [20, 38, 39, 40, 41, 42]. Plasma Ca++ concentration
and the corresponding plasma PTH concentration are measured at frequent time intervals.
Both hypo- and hyper-calcemia can be induced at a fast or a slow rate depending upon the
rate of infusion of sodium citrate or calcium gluconate, respectively. Examples of clamp tests
induced slowly [40] or rapidly [20] can be seen in Figure 3.1 and Figure 3.2, respectively. For
ease of illustration and analysis, typical time profiles of plasma Ca++ and PTH concentrations
for induced hypo- and hyper-calcemic clamp tests are depicted in Figure 3.3 and Figure 3.4,
respectively. Next, we present the dynamical model development.
3.3 Model Development
Based on the description of the PTH secretion process and its regulation in Sections 2.3
and clinical observations in Section 3.2 we consider two pools of PTH: one in the parathyroid
19
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(a) Typical time profiles of plasma Ca++ concentrations, x, during
induced hypocalcemic clamp tests. The dashed profile represents
a slower decrease and the solid profile represents a faster decrease
from initial steady-state Xi to a final steady-state Xf .
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(b) A typical PTH response, y, to slow
induction of hypocalcemia.
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(c) A typical PTH response, y,
to rapid induction of hypocalcemia.
Note the conspicuous peak.
Figure 3.3. An illustration of typical results in induced hypocalcemic clamp tests.
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(a) Typical time profiles of plasma Ca++ concentrations,
x, during induced hypercalcemic clamp tests. The dashed
profile represents a slow increase and the solid profile rep-
resents a rapid increase from initial steady-state Xi to a
final steady-state Xf .
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(b) A typical PTH response, y, to a slow induction of
hypercalcemia represented by the dashed line and a rapid
induction of hypercalcemia by represented by the solid
line. Note the inconspicuous dip in PTH response for the
rapid induction of hypercalcemia.
Figure 3.4. An illustration of typical results of induced hypercalcemic clamp tests.
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glands (PTG pool) and the other in plasma (plasma pool), as shown in Figure 3.5. In
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Figure 3.5. The Ca-PTH axis isolated from the qualitative model of calcium homeostasis
shown in Figure 2.7.
response to an acute decrease (time-scale of minutes) in plasma Ca++ concentration, signaling
pathways involving calcium sensors on the parathyroid chief cell stimulate exocytosis of the
PTH stored in the vesicles of the cells. Similarly, they inhibit exocytosis of the PTH in
response to a rise in the plasma Ca++ concentration. The PTH response occurs in time-scale
of minutes [20]. Since we are considering the response of PTH to acute changes in plasma
Ca++ concentration, we can assume the bio-synthesis rate of PTH to remain constant because
the regulation of PTH bio-synthesis in response to changes in the plasma Ca++ concentration
occurs in the times-scale of hours to days [1, 14, 18].
Using mass balance and assuming that we model average dynamics of n active chief cells
in the parathyroid glands, the rate of change of PTH in the PTG pool is given by
x˙1(t) = k︸︷︷︸
PTH production
− λCa(t)x1(t)︸ ︷︷ ︸
Secretion to plasma
− λ1x1(t)︸ ︷︷ ︸
Decay
, (3.1)
where x1(t) denotes the total amount of PTH in the PTG pool, k denotes the constant
production rate of PTH in the PTG pool, λCa(t) denotes the secretion rate function which
depends on plasma Ca++ concentration, and λ1 denotes the decay rate constant of PTH
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inside the parathyroid cells. We use the four-parameter reverse-sigmoidal relationship [33]
to relate λCa(t) and plasma Ca
++ concentration
λCa(t) =
A−B
1 +
(
Ca(t)
S
)m +B, (3.2)
where A and B denote maximal and minimal values of the secretion rate constant, Ca(t)
denotes plasma Ca++ concentration, and S is the value of Ca(t) when λCa =
A+B
2
, and m
gives the slope of the curve at S, respectively. These characteristic features of the reverse
sigmoid relationship are depicted in Figure 3.6. EM Brown originally used this relationship
Ca(t)
S
?Ca(t)
A
B
? = tan-1[m]
A+B
2
Figure 3.6. The reverse sigmoid curve.
[33] to relate PTH secretion rate and plasma Ca++ concentration. Note that we have used
the relationship to relate PTH secretion function (λCa(t)) to plasma Ca
++ concentration and
not PTH secretion (λCa) to plasma Ca
++ concentration. The rate of change of PTH in the
plasma pool is given by a mass balance relation
x˙2(t) = λCa(t)x1(t)︸ ︷︷ ︸
Secretion from parathyroid glands to plasma
−λ2x2(t)︸ ︷︷ ︸
Clearance
, (3.3)
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where x2(t) denotes the amount of PTH in the plasma pool and λ2 denotes the biological
clearance rate constant for PTH in circulation. Writing Equations (3.1) and (3.3) in a matrix
form
 x˙1
x˙2
 =
 −(λCa(t) + λ1) 0
λCa(t) λ2

 x1
x2
+
 k 0
0 0

 1
0
 , (3.4)
we observe that the two equations form a hierarchy of differential equations. We can solve
the first equation, which has a constant forcing function reflecting the assumption of constant
rate of PTH production at fast time-scale, to compute x1(t) and then substitute it into the
second equation to solve for x2(t).
Note that λCa is a function of time. Thus the dynamical system (3.4) is an LTV system.
The solution of the system is given by
x1(t) =φ1(t, t0)x10 + k
∫ t
t0
φ1(t, σ)dσ
x2(t) =φ2(t, t0)x20 +
∫ t
t0
φ2(t, σ)λCa(σ)x1(σ)dσ
t ≥ t0, x1(t0) = x10, x2(t0) = x20, (3.5)
where, φ1(t, t0), φ2(t, t0), φ1(t, σ), and φ2(t, σ) are transition scalars given by
φ1(t, t0) =e
−∫ tt0 (λCa(σ)+λ1)dσ = e−
∫ t
t0
(
A−B
1+(Ca(σ)S )
m+λ1
)
dσ
φ2(t, t0) =e
−∫ tt0λ2dσ
φ1(t, σ) =e
−∫ tσ(λCa(τ)+λ1)dτ = e−
∫ t
σ
(
A−B
1+(Ca(τ)S )
m+λ1
)
dτ
φ2(t, σ) =e
−∫ tσλ2dτ .
We have used Ca(t) = c1 + c2e
−λt and Ca(t) = c3 − c4e−λt to approximate calcium-time
profiles during hypo- and hyper-calcemic clamp tests [see Figure 3.8(a) and Figure 3.9(a)].
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Unfortunately, the solution (3.5) is analytically intractable because the integral terms on the
right-hand side cannot be solved in a closed form. One way to simplify the analysis is to
assume a step-change in calcium [19], which renders λCa(t) a constant and thus the system
(3.4) becomes an LTI. Using λCa(t) = λCa, and t0 = 0, we have
φ1(t, t0) =e
−(λCa+λ1)
∫ t
t0
dσ
= e−(λCa+λ1)t
φ2(t, t0) =e
−λ2
∫ t
t0
dσ
= e−λ2t
φ1(t, σ) =e
−(λCa+λ1)
∫ t
σdτ = e−(λCa+λ1)(t−σ)
φ2(t, σ) =e
−λ2
∫ t
σdτ = e−λ2(t−σ).
So, the solution is given by
x1(t) =
k
λCa + λ1
+
(
x10 − k
λCa + λ1
)
e−(λCa+λ1)t
x2(t) =
λCak
(λCa + λ1)λ2
+
(
x20 − λCak
(λCa + λ1)λ2
+
λCax10
(λCa + λ1 − λ2) −
λCak
(λCa + λ1) (λCa + λ1 − λ2)
)
e−λ2t
+
(
λCak
(λCa + λ1) (λCa + λ1 − λ2) −
λCax10
(λCa + λ1 − λ2)
)
e−(λCa+λ1)t.
In practice, Ca++ concentration changes at a much slower rate than a step. So the
step-change assumption in plasma Ca++ concentration is not valid. Moreover, plasma PTH
response depends on the rate of change of plasma Ca++ concentration [38, 43]. Thus a model
has to be able to capture the expected time-varying nature of the system (3.4). Next we
present our computational approach for parameterizing the system equations.
3.3.1 Model parametrization
We start by deriving parameter constraints of the system (3.1)-(3.3) at steady-state. We
then use both known data and a guided iterative procedure to match clinical tests. In the
following subsections we describe the model parametrization steps.
27
3.3.1.1 Deriving parameter constraints at steady-state
At steady-state, (3.1) becomes
k =
[
A−B
1 +
(
CaSS
S
)m +B
]
x1,SS + λ1x1,SS, (3.6)
where x1,SS and CaSS denote steady-state values of PTH in the PTG pool and plasma Ca
++
concentration in plasma, respectively. Similarly, (3.3) becomes
[
A−B
1 +
(
CaSS
S
)m +B
]
x1,SS =λ2x2,SS, (3.7)
where x2,SS denotes steady-state values of PTH concentration in plasma. From (3.6) and
(3.7) we have
k =λ2x2,SS + λ1x1,SS. (3.8)
Considering normal steady-state1 values of a healthy individual, 3.8 becomes
k =λ2x2,SS,N + λ1x1,SS,N, (3.9)
where x1,SS,N and x2,SS,N are steady-state values of PTH in the PTG pool and PTH in plasma
of a healthy individual, respectively. Since the steady-state PTH secretion rate in response
to acute changes in plasma Ca++ has maximum and minimum saturation values [33], we
assume that there is a maximum or a minimum saturation steady-state value that plasma
PTH concentration can attain as well. At extreme values, (3.8) becomes
k = λ2x2,SS,Min + λ1x1,SS,Max, (3.10)
1By normal steady-state we mean the average concentrations of either plasma Ca++ or PTH when an
individual is not under clamp test.
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and
k = λ2x2,SS,Max + λ1x1,SS,Min, (3.11)
where x1,SS,Max and x1,SS,Min denote maximum and minimum steady-state values of PTH
in the PTG pool, respectively, and x2,SS,Min and x2,SS,Max denote minimum and maximum
steady-state values of PTH in the plasma pool, respectively. Evaluating (3.7) at upper and
lower plasma Ca++ levels we have
lim
Ca→0
Ax1,SS,Min = λ2x2,SS,Max =⇒ A = λ2x2,SS,Max
x1,SS,Min
, (3.12)
lim
Ca→∞
Ax1,SS,Max = λ2x2,SS,Min =⇒ B = λ2x2,SS,Min
x1,SS,Max
. (3.13)
Finally, the set point S can be isolated from (3.2) as follows
S = exp
log (CaSS)− 1
m
log

 A−B
λ2x2,SS
x1,SS
−B
− 1

 . (3.14)
Relevant steady-state data is listed in Table 3.1 obtained from [20]. Since our model is based
Variables Concentration Units
x2,SS,N 2.41 pmolL
−1
x2,SS,Max 5.20 pmolL
−1
x2,SS,Min 0.96 pmolL
−1
CaSS,N 1.23 mmolL
−1
Table 3.1. Average steady-state plasma PTH (x2,SS) and Ca
++ concentrations from 7
healthy individuals obtained from Figure 3.2 [20].
on mass balance, the available data in concentration units (pmolL−1) have been multiplied
29
by average adult plasma volume, ≈ 2.75 L [44], to convert into pmols and listed in Table
3.2.
Variables Amount Units
x2,SS,N 6.63 pmol
x2,SS,Max 14.39 pmol
x2,SS,Min 2.65 pmol
Table 3.2. Data from Table 3.1 converted into pmols.
There are 10 unknowns, k, λ1, λ2, x1,SS,N, x1,SS,Max, x1,SS,Min, A, B, S, and m, in the
6 equations (3.9)-(3.14). If we know the values of λ1, λ2, x1,SS,N, and m we can get a
closed form solution for the rest of the unknowns. These four unknowns can have infinite
number of possible values. Our aim is to find values that make appropriate biological sense.
The resulting numerical solution of (3.1)-(3.3) should also match well with the clinical data
(presented in Section 3.2). Next, we present some information that we utilized to define a
reasonable starting values of these four unknowns.
3.3.1.2 Estimating starting values of λ1, λ2, x1,SS,N, and m
1. The half-life of PTH in circulation, τ2 =
ln(2)
λ2
, has been reported to vary from 2 to 15
minutes in [19], 2.04-2.93 minutes in [20], and 2.5 in [37]. The later also states that
these values represent upper estimates, as any continued PTH release above the post
infusion baseline during the decay measurements would slightly prolong the calculated
half-life. Hence, we assume plasma PTH disappearance half life in a healthy adult to
be less than 15 minutes. As a starting value we used τ2=2.5 minutes. So, λ2 =
ln(2)
τ2
.
2. We assume that the half-life of PTH in the parathyroid cell, τ1 =
ln(2)
λ1
, is much greater
than τ2, since there is no clearance by kidney or liver while the PTH is still in the chief
cell. As a starting value we have used τ1= 30 minutes. So, λ1 =
ln(2)
τ1
.
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3. We assume that x1,SS,N >> x2,SS,N when there is no acute disturbance in the plasma
calcium level. Clinical data in [20, 38] suggests that a sustained high PTH secretion
rate is possible for hours during sustained hypocalcemia. Since the rate of biosynthesis
doesn’t vary substantially in that time scale [1, 14, 19], this sustained secretion of PTH
at a higher rate is only possible if there is a very large storage of PTH in the vesicles
of the PTG pool. Thus, we have used x1,SS,N = 10× x2,SS,N as the starting value.
4. The parameter m controls the sensitivity of λCa(t) with respect to the plasma Ca
++
concentration. We have used m = 100 as a starting point, assuming a very high
sensitivity consistent with observations from clinical data [33, 42].
At this point we only know the starting guess values of the four unknowns λ1, λ2, x1,SS,N,
and m which we will use for the guided iteration. The next step is to calculate k, x1,SS,Max,
x1,SS,Min, A, B, and S.
3.3.1.3 Calculating k, x1,SS,Max, x1,SS,Min, A, B, and S
We use the six equations (3.9)-(3.14) to calculate k, x1,SS,Max, x1,SS,Min, A, B, and S
respectively:n
k = λ2x2,SS,N + λ1x1,SS,N,
x1,SS,Max =
k − λ2x2,SS,Min
λ1
,
x1,SS,Min =
k − λ2x2,SS,Max
λ1
,
A =
λ2x2,SS,Max
x1,SS,Min
,
B =
λ2x2,SS,Min
x1,SS,Max
, and
S = exp
log (CaSS)− 1
m
log

 A−B
λ2x2,SS
x1,SS
−B
− 1

 .
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At this point we have estimated the values of all the parameters k, λ1, λ2, A, B, S,
and m for our model (3.1)-(3.3). The next step is to see if our model simulation can match
clinical data of a hypocalcemic clamp test using these values. For this, we looked to match
the features of the curve such as the peak value Ymax, the time taken to reach this value
tmax, and the rate of exponential decrease of plasma PTH concentration from Ymax to the
final steady-state Yf as shown in Figure 3.3. The next step is to tune the values of the four
parameters: λ1, λ2, x1,SS,N, and m from the starting values mentioned in Section 3.3.1.2
in an iterative fashion to get a better match. Some observations made during this tuning
process were used as guidelines for tuning process as described in the following section.
3.3.1.4 Guidelines for tuning λ1, λ2, x1,SS,N, and m
1. Increasing τ1 (or decreasing λ1) increases Ymax, decreases tmax and increases the rate
of exponential decrease of PTH after peak in PTH response.
2. Increasing τ2 (or decreasing λ2) decreases Ymax and increases tmax and decreases the
rate of exponential decrease of PTH after peak in PTH response.
3. Increasing x1,SS,N decreases Ymax and increases tmax larger.
4. Increasing m increases Ymax and increases tmax larger.
The above guideline is diagrammatically represented in Figure 3.7. Using these guidelines
we iteratively tune the values of λ1, λ2, x1,SS,N, and m until we achieve a good match with
the hypocalcemic clamp test data.
This guided iterative process results in the parameter values listed in Table 3.3. The
values of the remaining unknown parameters calculated from the steady-state relations (3.9)-
(3.14) are listed in Table 3.4. Using these parameters, our simulation result (Figure 3.8(b))
matches very well with the plasma PTH response presented in Figure 3.2(b) for the calcium
input as shown in Figure 3.2(a).
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Result
Action
Ymax tmax
Rate of Exponential Decrease 
of PTH after Peak
?1
?2
X1,SS,N -
m -
Figure 3.7. The qualitative effects of tuning the parameters on PTH response for hypocal-
cemic clamp test simulation.
Parameters Values Units
τ1 55.0000 min
λ1 0.0126 min
−1
τ2 1.8000 min
λ2 0.3851 min
−1
x1,SS,N 321.7500 pmol
m 170.0000 −
Table 3.3. Values of model parameters tuned to fit average induced hypocalcemic clamp
test data obtained from 7 healthy individuals in Figure 3.8(b) [20].
Next, we used this model to predict the dynamics of hypercalcemic clamp test conducted
on the same set of healthy subjects (Figure 3.2(d)). The same model, with the same set
of parameters as in Table 3.3 successfully predicted observed clinical data as seen in Figure
3.9(b).
3.3.2 Guided iterative parametrization scheme
Listed below are the general steps used to parameterize our model:
1. Derive steady-state relations (3.9)-(3.14).
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(b) PTH response for induced hypocalcemia (output).
Figure 3.8. Clinical (dots) vs. tuned-model simulation (solid lines) result of an induced
hypocalcemic clamp test. Clinical data represents the average response of 7 healthy subjects
[20].
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(b) PTH response for induced hypercalcemia (output).
Figure 3.9. Clinical (dots) vs. prediction by tuned-model (solid lines) of an induced
hypercalcemic clamp test. Clinical data represents the average response of 7 healthy subjects
[20].
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Parameters Values Units
k 6.6102 pmol/min
x1,SS,Max 443.5062 pmol
x1,SS,Min 84.6236 pmol
A 0.0655 pmol/min
B 0.0023 pmol/min
S 1.2159 mmol/L
Table 3.4. Values of model parameters calculated using Table 3.3 and equations (3.9)-(3.14).
2. Estimate the starting values of λ1, λ2, x1,SS,N, and m based on the guidelines presented
in the Subsection 3.3.1.2.
3. Calculate k, x1,SS,Max, x1,SS,Min, A, B, and S using (3.9)-(3.14), using the starting
guess from step 2 and the available steady-state data for x2,SS,N, x2,SS,Max, x2,SS,Min,
and CaSS,N.
4. Use the values of k, λ1, λ2, A, B, S, and m obtained from steps 2 and 3 to produce
the response of our model (3.1)-(3.3) to the input approximating data presented in
Figure 3.8(a) numerically using a simulink model in matlab.
5. Compare the clinical data and model simulation [Figure 3.8(b)] with respect to various
features of the curve such as Ymax, tmax and the rate of exponential decrease of PTH
after peak. If they don’t match well , tune the value of one of the parameters λ1, λ2,
x1,SS,N, and m based on the guidelines set forth in subsection 3.3.1.4 and go to step 3.
Stop if a favorable match is achieved between them.
The final result obtained by following the guided iterative parametrization scheme as de-
scribed above is presented in Figure 3.8(b).
To further test our model and the guided iterative parametrization scheme, we obtained
proprietary data from the lead author of [20], Prof. Claus P Schmitt, Division of Pediatric
36
Nephrology, University of Heidelberg, Germany. These data describe the responses of 3
healthy individuals to hypo- and hyper-calcemic clamp test. From these data we found the
steady-state values for x2,SS,N, x2,SS,Max, x2,SS,Min, and CaSS,N for these individuals which has
been tabulated in Table 3.5. We followed the guided iterative parametrization scheme pre-
sented in Section 3.3.2. The final values of λ1, λ2, x1,SS,N, and m tuned to match the induced
hypocalcemic clamp test data appear in Table 3.6. The calculated values of the unknown
parameters in the steady-state Equations (3.9)-(3.14) are given in Table 3.7. The results
of model parametrization and model prediction for these data from individual subjects are
shown in Figures 3.10-3.15. Note that for the induced hypercalcemic clamp test for individ-
ual subjects (e.g., Figure 3.11), a portion of the transient data is missing. Unfortunately,
this data could not be made available by Prof. Schmitt.
Subject x2,SS,N (pmolL
−1) x2,SS,Min (pmolL−1) x2,SS,Max (pmolL−1) CaSS,N (mmolL−1)
1 2.6767 0.4896 6.0320 1.2000
2 2.7527 0.5077 6.2027 1.2475
3 3.1044 0.7573 6.8011 1.2500
Table 3.5. Steady-state data of the individual subjects.
Subject τ1 (min) λ1 (min
−1) τ2 (min) λ2 (min−1) x1,SS,N (pmolL−1) m
1 48.0 0.0144 1.43 0.4647 412.50 100
2 21.0 0.0330 0.70 0.9902 412.50 100
3 49.5 0.0140 1.10 0.6301 563.75 50
Table 3.6. Values of model parameters tuned to fit induced hypocalcemic clamp test data
of the individual subjects.
Based on the successful predictive tests presented in this chapter we conclude that our
two-pool, linear, time-varying model (3.1)-(3.3) provides a reasonable description of expected
dynamics of the Ca-PTH axis. This is the first report of its kind to the best of our knowledge.
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(b) PTH response for induced hypocalcemia (output).
Figure 3.10. Clinical (dots) vs. tuned-model simulation (solid line) of an induced hypocal-
cemic clamp test conducted on a healthy individual (Subject 1). Clinical data provided by
the lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology, University
of Heidelberg, Germany.
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(b) PTH response for induced hypercalcemia (output).
Figure 3.11. Clinical (dots) vs. prediction by tuned-model (solid line) of an induced
hypercalcemic clamp test conducted on a healthy individual (Subject 1). Clinical data
provided by the lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology,
University of Heidelberg, Germany. Note: Prof. Schmitt could provide only the steady-state
data but not the transient data for the PTH response.
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(b) PTH response for induced hypocalcemia (output).
Figure 3.12. Clinical (dots) vs. tuned model simulation (solid line) results of an induced
hypocalcemic clamp test conducted on a healthy individual (Subject 2) provided by the
lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology, University
of Heidelberg, Germany. Note the non-smooth nature of Ca++ which translates into non-
smooth PTH response at >600 minutes. This prediction is based on the smooth (solid) Ca++
dynamics shown in (a). So such non-smooth behavior is not accounted for.
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(b) PTH response for induced hypercalcemia (output).
Figure 3.13. Clinical (dots) vs. prediction by tuned-model (solid line) of an induced
hypercalcemic clamp test conducted on a healthy individual (Subject 2). Clinical data
provided by the lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology,
University of Heidelberg, Germany.
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(b) PTH response for induced hypocalcemia (output).
Figure 3.14. Clinical (dots) vs. tuned-model simulation (solid line) of an induced hypocal-
cemic clamp test conducted on a healthy individual (Subject 3). Data provided by the
lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology, University of
Heidelberg, Germany.
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(b) PTH response for induced hypercalcemia (output).
Figure 3.15. Clinical (dots) vs. prediction by tuned-model (solid line) of an induced
hypercalcemic clamp test conducted on a healthy individual (Subject 3). Clinical data
provided by the lead author of [20], Prof. Claus P Schmitt, Division of Pediatric Nephrology,
University of Heidelberg, Germany. Note: Prof. Schmitt could provide only the steady-state
data but not the transient data for the PTH response.
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Subjects k x1,SS,Max x1,SS,Min A B S
1 9.5247 614.3838 102.7813 0.0782 0.0011 1.1737
2 21.1112 597.7091 127.8721 0.1321 0.0023 1.2231
3 13.2737 854.2064 106.2867 0.1109 0.0015 1.1881
Units pmolL−1min−1 pmolL−1 pmolL−1 min−1 min−1 mmolL−1
Table 3.7. Values of model parameters for individual subjects calculated using Table 3.6
and equations (3.9)-(3.14).
The guided iterative method that relies on the available clinical data and biologically-driven
assumptions provides a simple and an intuitive parametrization of our model. In the next
chapter, we turn our focus to the calcium-PTH (Ca-PTH) reverse sigmoid curve.
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CHAPTER 4
THE CA-PTH REVERSE SIGMOID CURVE
The reverse sigmoid curve describing steady-state Ca-PTH relationship has been sug-
gested as a possible bio-tool for assessing health and disease states associated with calcium
homeostasis [40, 41, 45, 46]. However, our analysis revealed that the accepted method im-
plemented to quantify this curve has certain weaknesses. In this context, we present a new
protocol to obtain a consistent Ca-PTH reverse sigmoid curve that is independent of the
dynamics of the Ca-PTH axis and the induced calcemic clamp test procedure. We begin
with a literature review.
4.1 Literature review
The reverse sigmoid relationship between plasma Ca++ and PTH concentrations in vivo
was first reported in 1974 in Jersey cows from the plasma samples collected before, during
and after parturition [47]. In 1978 Mayer, one of the co-authors of [47], and Hurst reported a
reverse sigmoid relationship between plasma Ca++ concentration and PTH secretion rate [48].
Instead of measuring plasma PTH concentration, PTH secretion rate was measured directly
by collecting PTH gland effluent blood samples from cows at regular intervals to measure
the blood flow rate and the concentrations of PTH. The experiment was conducted over a
period of 5 to 7 hours. Brown et al., also in 1978, studied the relationship of PTH release
to Ca++ concentration in vitro [49]. The study was conducted on dispersed parathyroid
cells of normal and abnormal parathyroid tissues from patients with adenoma or primary
hyperplasia. Brown et al. published a series of similar studies conducted on the dispersed
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parathyroid cells from patients with hyperparathyroidism [50], adenoma [51] and secondary
hyperparathyroidism due to chronic renal failure [52]. In 1983, EM Brown, for the first
time proposed the four parameter mathematical model [33] to describe the reverse sigmoidal
relationship between parathyroid hormone release and Ca++ concentration in vitro observed
in earlier data [49, 50, 51, 52]. This model was described by
y =
A−B
1 +
(
x
S
)m +B (4.1)
where y denotes PTH secretion rate, x denotes the Ca++ concentration, A denotes maximal
PTH secretion rate, B denotes minimal PTH secretion rate, S denotes the value of x at
which y = A+B
2
, and m denotes the slope of the curve at S as shown in Figure 4.1.
x
y
S
A
B
? = tan-1[m]
A+B
2
Figure 4.1. A reverse sigmoid curve.
Hysteresis in the relationship between the plasma Ca++ and PTH concentrations was
reported in [39]. Hysteresis of PTH response to hypocalcemia in hemodialysis patients
with bone disease was reported in [53]. In [42] it has been hypothesized that hysteresis in
the relationship between plasma Ca++ concentration and PTH secretion in normal animals
and humans and in hemodialysis patients results from a sensing of directional change or
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acceleration or deceleration in the rate of change of the plasma Ca++ concentration by the
parathyroid glands.
Numerous clinical studies utilized the reverse sigmoid curve to find possible correla-
tion with normal and diseased calcium homeostasis. For example, studies conducted on
patients with familial benign hypercalcemia and primary hyperparathyroidism were pre-
sented in [46], and secondary hyperparathyroidism in [40, 41]. Studies conducted on pa-
tients undergoing hemodialysis were presented in [45], hemodialysis with marked secondary
hyperparathyroidism in [54], uremic patients on dialysis in [43, 55], and haemodialysis
with different forms of renal osteodystrophy in [56] Studies conducted on normal indi-
viduals were presented in [57], and hyperparathyroidism patients before and after total
parathyroidectomy with autotransplantation were presented in [58]. The above references
[40, 41, 43, 45, 46, 54, 55, 56, 57, 58] discussed the similarities and differences in the char-
acteristic features of a reverse sigmoid curve such as the set-point, the slope of the curve at
set-point and the maximal or minimal plasma PTH concentration.
The effect of using different methods of calculation on assessment of the set-point in the
calcium-PTH reverse sigmoid has been studied in [59]. The dependence of the characteristic
features of a reverse sigmoid curve on the rate of change of plasma Ca++ was first presented
in [38]. Dependence of plasma PTH response on the rate of change of Ca++ concentration
was also reported in [43, 60, 61]. Next, we describe the current method used to obtain
Ca-PTH reverse sigmoid curve in vivo based on the references cited in this section.
4.2 Current method to obtain the Ca-PTH reverse sigmoid curve
The current method of obtaining a Ca-PTH reverse sigmoid curve involves, in general,
slowly induced hypo- and hyper-calcemic clamp tests conducted on a set of subjects to obtain
plasma Ca++ and PTH concentrations measurements at frequent intervals. An example is
shown in Figure 4.2 [40]. In this particular example, hypo- and hyper-calcemic clamp tests are
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conducted on two sets of subjects: patients with secondary hyperparathyroidism and normal
individuals. Plasma Ca++ and PTH concentrations are measured every 10 minutes during
the test periods of 120 minutes (Figure 4.2). Corresponding plasma Ca++ concentration
and PTH concentration values of patients with secondary hyperparathyroidism and normal
individuals [40] are plotted in Ca-PTH graph to obtain the reverse sigmoid curves as shown
in Figure 4.3. Note the differences in the features such as set-point values, slope of the curve
Figure 4.3. A typical calcium-PTH reverse sigmoid curve corresponding to the data shown
in Figure 4.2. Solid dots represent data of healthy subjects. Squares represent data of
patients with secondary hyperparathyroidism. Scanned from [40].
at the set-point and the minimal saturation values of plasma PTH concentration between
the curves obtained for the two sets of subjects. The purpose of this discussion is to give
readers an idea of how the Ca-PTH reverse sigmoid curve is obtained. So, we will not get
into details of significance of these differences. Next, we present a limitation of the current
method to plot Ca-PTH reverse sigmoid curve.
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4.3 A limitation of the current method
Taking pairs of points at arbitrary times can lead to a misleading curve. For example,
consider a rapidly induced calcemic clamp test [20] as shown in Figure 4.4. The curve
obtained by plotting corresponding plasma Ca++ and PTH concentrations is not a reverse
sigmoid [62] in shape as shown in Figure 4.5. It appears that one cannot select any arbitrary
pair of (plasma Ca++ concentration, plasma PTH concentration) data points to construct
the reverse sigmoid curve. Next, we use our model to analyze this problem of obtaining a
meaningful Ca-PTH curve.
4.4 Analysis of simulation results
The model developed in Chapter 3 is described by
 x˙1
x˙2
 =
 −(λCa(t) + λ1) 0
λCa(t) λ2

 x1
x2
+
 k 0
0 0

 1
0
 , (4.2)
where
λCa(t) =
A−B
1 +
(
Ca(t)
S
)m +B. (4.3)
For simulation purposes, the parameter values of the model parameterized for the third sub-
ject from Tables 3.7-3.5 are used. Figure 4.6 represents the simulation for induced hypocal-
cemic clamp test, where Ca(t) = c1 + c2e
−σt. Plasma Ca++ concentration is decreased at
a slower rate initially, represented by the profile with σ1 and subsequently at progressively
faster rates, represented by σ2, and σ3 as shown in Figure 4.6(a), to a same lower steady-state
value (σ1 < σ2 < σ3). Note that for the slowest rate calcium input, the corresponding PTH
response doesn’t show a peak as shown in Figure 4.6(b). But for the faster rate calcium
inputs, peaks in the PTH responses are conspicuous. The peak value progressively increases
as the calcium input rate becomes faster. A step input produces the maximum value of the
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Figure 4.5. A calcium-PTH curve that would result from the conventional approach using
data from a rapidly induced calcemic clamp test [20]. This curve doesn’t resemble the
expected reverse sigmoidal shape. Scanned from [62].
peak and smallest tmax. This result is consistent with the observation made in [38] (Figure
4.7) in which hypocalcemia was induced in healthy subjects to attain multiple intermediate
steady-states. Same intermediate steady-state of plasma Ca++ concentration was achieved
at a faster and a slower rate as shown in Figure 4.7(a). The faster decrease in plasma Ca++
concentration produced higher peak in the PTH response as shown in Figure 4.7(b). The
PTH responses appear to settle at same value after each 30 minutes duration for both faster
and slower hypocalcemia induction.
Figure 4.8 represents the simulation of an induced hypercalcemic clamp test where
Ca(t) = c3 − c4e−σt. Plasma Ca++ concentration is increased at a slower rate initially,
represented by the profile with σ1 and subsequently at progressively faster rates, repre-
sented by σ2, and σ3, as shown in Figure 4.8(a), and eventually to a lower steady-state
value (σ1 < σ2 < σ3). Note that for the slowest rate calcium input, the corresponding PTH
response doesn’t show a dip as shown in the Figure 4.8(b). With progressively faster rate cal-
cium inputs, the dips in the PTH responses become more prominent. A step input produces
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(a) Induced hypocalcemia at varying rates (input). σ1 < σ2 < σ3.
(b) Corresponding PTH response (output).
Figure 4.6. Simulation of PTH response for hypocalcemia induced at varying rates. The
model was parameterized using data from healthy subject 3 (Figure 3.14 and Tables 3.5-3.7).
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(a) Induced hypocalcemia attaining multiple
intermediate steady-states. Same intermedi-
ate steady-state of plasma Ca++ concentra-
tion was achieved at a faster (dots) and a
slower (circles) rate.
(b) PTH response corresponding to Figure (a).
Note the higher peaks in the PTH responses corre-
sponding to faster change in Ca++ (dots) and lower
peaks corresponding to slower change in Ca++ (cir-
cles). The responses appear to settle at same value
after each 30 minutes duration.
Figure 4.7. An induced hypocalcemic clamp test. Scanned from [38].
the minimum dip value and smallest tmax. Unfortunately, we could not find the appropriate
published data for comparison. However, one thing seems to be consistent, that is, the dips
for PTH response obtained during hypercalcemic clamp tests are not as conspicuous as the
peaks obtained during hypocalcemic clamp tests. The simulations shows that even for the
fastest (step) increase in plasma Ca++ concentration, there isn’t a conspicuous dip in the
PTH response profile. This is again consistent with the observed clinical data [20] in which
plasma Ca++ concentration has been raised very fast but the resulting PTH response doesn’t
show a conspicuous dip (Figure 4.4(c)-(d)).
In addition to issues related to its construction, there appears to be some confusion as
to what the reverse sigmoid model actually represents. Some researchers have used it to
represent steady-state PTH secretion rate vs steady-state plasma Ca++ concentration [33],
some researchers have used it to represent PTH secretion rate as a function of plasma Ca++
concentration in the dynamical model of the Ca-PTH axis [35], while most have used it to
represent relationship between plasma PTH concentration and plasma Ca++ concentration
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(a) Induced hypercalcemia at varying rates (input). σ1 < σ2 < σ3.
(b) Corresponding PTH response for induced hypocalcemia (output).
Figure 4.8. Simulation of PTH response for hypercalcemia induced at varying rates. The
model was parameterized using data from healthy subject 3 (Figure 3.14 and Tables 3.5-3.7).
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during induced hypo- and hyper- calcemic clamp test [40, 41, 43, 45, 46, 54, 55, 56, 57, 58,
59]. These papers present clinical studies based on the characteristic features of the reverse
sigmoid curve such as the set-point, the slope of the curve at set point, and the maximal or
minimal plasma PTH concentrations to find a possible explanation of normal and diseased
states of calcium. The method used to plot the reverse sigmoid curve has been presented
in Section 4.2. We note that [19] used it to represent the secretion-rate function in the
two-pool LTI model. Let us study these differing interpretations using our model. Recalling
the steady-state Equations (3.6) and (3.7):
k =
[
A−B
1 +
(
CaSS
S
)m +B
]
x1,SS + λ1x1,SS,
λ2x2,SS =
[
A−B
1 +
(
CaSS
S
)m +B
]
x1,SS,
and using y = x2,SS (steady-state plasma PTH level) and x = CaSS (steady-state plasma
Ca++ concentration ), we get
y(x) =
k
λ2
 1
1 + λ1A−B
1+( x
S
)m
+B
 .
Evaluating limits,
ymax ≡ lim
x→0
y =
k
λ2
[
1
1 + λ1
A
]
ymin ≡ lim
x→∞
y =
k
λ2
[
1
1 + λ1
B
]
.
Since A > B from the definition of the curve, it follows that, ymax > ymin for all x ∈ [0,∞].
Next, let us rewrite y(x) as
56
y(x) =
k
λ2
 1
1 + λ1A−B
1+( x
S
)m
+B
 = k
λ2

(
A−B
1+( x
S
)m
+B
)
(
A−B
1+( x
S
)m
+B
)
+ λ1
 = k
λ2
[
A+ B
Sm
xm
A+ B
Sm
xm + λ1 +
λ1
Sm
xm
]
.
Differentiating with respect to x gives
dy
dx
=
k
λ2
d
dx
[
A+ B
Sm
xm
A+ B
Sm
xm + λ1 +
λ1
Sm
xm
]
=
k
λ2
(
A+ B
Sm
xm + λ1 +
λ1
Sm
xm
)
B
Sm
mxm−1 − (A+ B
Sm
xm
) (
B
Sm
mxm−1 + λ1 + λ1Smmx
m−1)(
A+ B
Sm
xm + λ1 +
λ1
Sm
xm
)2
=− k
λ2
(A−B) λ1
Sm
mxm−1(
A+ B
Sm
xm + λ1 +
λ1
Sm
xm
)2 .
Since (A−B) > 0 and A, B, k, x, λ1, λ2, S, m > 0, it follows that dydx < 0. Thus, y(x) is
a monotonically decreasing function. Since we already showed that y(x) is bounded above
by ymax and bounded below by ymin, the model implies that a reverse sigmoidal relationship
exists between plasma Ca++ and PTH concentrations at steady-state. Now if we consider
that the reverse sigmoid relationship represents the model for PTH secretory rate as a func-
tion of plasma Ca++ concentration as in [33, 35], the dynamical model for the rate of change
of plasma PTH concentration from Section 3.3 becomes
x˙2(t) =
A− B
1 +
(
Ca
S
)m + B︸ ︷︷ ︸
Secretion to plasma from parathyroid gland
−λ2x2(t).︸ ︷︷ ︸
Clearance
Note that the system has been reduced into single pool model. For x2(t0) = 0 at t0 = 0, the
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solution of the above system is given by
x2(t) =
∫ t
t0
 A− B
1 +
(
Ca(t)
S
)m + B
 e−λ2σ dσ , t ≥ t0, x2(t0) = 0, t0 = 0.
Considering a step decrease in calcium
Ca(t) = Ca, t < t0
= 0, t ≥ t0
the solution can be simplified to
x2(t) =
(
A− B
1 +
(
Ca
S
)m + B
)∫ t
t0
e−λ2σ dσ =
(
A− B
1 +
(
Ca
S
)m + B
)(
1− e−λ2t
λ2
)
.
Here, due to (1− e−λ2t), the time profile of the solution always looks like Figure 3.3(b) and
can never exhibit the peak shown in Figure 3.3(c). But we know from the clinical data in
[20, 38] that even much slower changes in plasma Ca++ result in plasma PTH responses as
shown in Figure 3.3(c).
Based on above analysis, we conclude that the reverse sigmoid model should not be used
to represent the secretion rate as a function of plasma Ca++ concentration in the dynamical
model for calcium-PTH axis. In fact, the reverse sigmoid relationship presented in [33]
is nothing but the curve fitting done for approximated steady-state values of Ca++ and
corresponding PTH secretion rates in vitro. Moreover, the clinical studies based on the
characteristic features of the reverse sigmoid curve such as the set-point, the slope of the
curve at set point and the maximal or minimal plasma PTH concentrations to find a possible
explanation of normal and diseased states of calcium homeostasis in [40, 41, 43, 45, 46, 54, 55,
56, 57, 58, 59] used transient data to construct the curve, rendering the results questionable.
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We also noted that PR Conlin with his colleagues including EM Brown reported hysteresis
in the relationship between plasma Ca++ and PTH concentration [39] using transient data.
Since a hysteresis curve should represent only the steady-state values [63, 64], the reported
hysteresis is questionable. Hysteresis of PTH response to hypocalcemia in hemodialysis
patients with bone disease was reported in [42, 53]. Unfortunately, this claim was also based
on the transient data. Next, we propose a new protocol to construct a Ca-PTH reverse
sigmoid curve to overcome the limitations of present procedures.
4.5 The new protocol
Consider the three asymptotes L1, L2, and L3 in the Ca-PTH reverse sigmoid curve as
shown in Figure 4.9:
Upper Saturation level
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P3 P4
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n
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L3 L1
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Figure 4.9. Constructing the Ca-PTH reverse sigmoid curve.
1. Asymptote L1 passing through the upper saturation level,
2. asymptote L2 passing through the lower saturation level, and
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3. asymptote L3 passing through the normal region.
We need at least 2 points to define each of these asymptotes. Therefore, a minimum of
6 points are required to construct a working reverse sigmoid curve. Induced hypocalcemic
clamp tests should be conducted to obtain three steady-state data points P1, P2, and P5 and
induced hypercalcemic clamp tests should be conducted to obtain three steady-state data
points P3, P4,and P6. Note that P5 and P6 should be very close to PN corresponding to the
normal plasma Ca++ and PTH concentration values. Assuming that the curve is linear in
this neighborhood, they define L3.
In conclusion, we state that:
1. reverse sigmoid model should not be used to represent the secretion rate in the dynam-
ical model of calcium-PTH axis, but should only be used to represent the secretion
rate function,
2. only steady-state data should be used in plotting Ca-PTH reverse-sigmoid curve to
obtain consistent result and meaningful interpretation,
3. only steady-state data should be used in the investigation of possible hysteresis in
relationship between plasma PTH and Ca++ concentrations, and
4. if transient data are used, then the resulting curve becomes dependent on the particular
subject’s axis dynamics or the calcemic clamp test procedure rendering such studies
unreliable. Transient data can be useful only to study the overall dynamic response of
plasma PTH to the changes in plasma Ca++ concentration.
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CHAPTER 5
CONCLUSIONS
In this thesis a two-pool, linear, time-varying model was developed to describe the acute
Ca-PTH axis dynamics. This model, parameterized based on clinical data from hypocalcemic
clamp test successfully predicted PTH response for hypercalcemic clamp test in healthy hu-
mans. Using analysis and simulation, we proposed a new protocol for the construction of the
Ca-PTH reverse sigmoid curve, an integral part of this model. The proposed protocol over-
comes limitations of current procedures in that it is independent of the particular subject’s
axis dynamics or the manner by which the calcemic clamp test is conducted. This model is
a good candidate for inclusion in an overall calcium homeostasis model that may be used to
study the health and disease associated with calcium homeostasis.
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